Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice.
Level 5 - mechanism / opinion, no new human data
Preclinical animal study in mice (CEBM Level 5).
PubMed 21270251 · doi:10.2337/db10-0426
What was done
Researchers evaluated the necessity of glucagon signaling in the development of insulin-deficient type 1 diabetes. Glucagon receptor knockout (Gcgr-/-) mice and wild-type (Gcgr+/+) control mice received a double dose of streptozotocin to induce complete beta-cell destruction, followed by metabolic and clinical tracking.
What was found
Wild-type controls developed severe diabetes, exhibiting blood glucose >500 mg/dL, hyperketonemia, polyuria, and cachexia requiring euthanasia by 6 weeks. Despite equivalent beta-cell destruction, Gcgr-/- mice developed no clinical or laboratory signs of diabetes. They exhibited alpha-cell hyperplasia and high plasma glucagon (~1,200 pg/mL), but hepatic phosphorylated CREB and phosphoenolpyruvate carboxykinase mRNA were profoundly reduced. Fasting glucose, oral glucose tolerance, and intraperitoneal glucose tolerance remained normal, while fasting/nonfasting free fatty acids and nonfasting beta-hydroxybutyrate levels were lower than controls.
Why it matters
This study demonstrates that the severe clinical symptoms and metabolic collapse of absolute insulin deficiency in mice are dependent on glucagon signaling, establishing glucagon receptor antagonism as a potential therapeutic target in type 1 diabetes.
Limits
The study was conducted entirely in a rodent model using chemically induced (streptozotocin) beta-cell destruction, which does not fully capture human autoimmune type 1 diabetes. Sample sizes and exact quantitative variance were not reported in the abstract, and systemic long-term consequences of chronic alpha-cell hyperplasia were not detailed.
Cited by
- supports Dr. Roger Unger published papers demonstrating that inhibiting glucagon excess in type 1 diabetes corrects hyperglycemia without requiring insulin administration.